Polypodium preparation
| Polypodium preparation | Result of interest | Photoprotective activity (assays) | Radiation type | Route and dose | Refs. |
|---|---|---|---|---|---|
| Capsule | Significant reduction of cutaneous reaction and symptoms/photoprotection treatment in idiopathic photodermatosis | In vivo—human | UVA/UVB | Oral Used dose: 480 mg/day | [18] |
| Capsule | Decreased erythema/increased minimal erythema dose (MED) | In vivo—human | UVB | Oral Used dose: 120–1,080 mg/day | [16, 40, 77] |
| Hydrophilic extract | Prevention and delay of typical lesions (eruptions) caused by UVR | In vivo—human | UVA/UVB | Oral Used dose: 720, 960, 1,200 mg/day | [14] |
| Extract | Inhibition of elastase activity/stimulation of cell expression/strengthening cell matrix/prevention in photoaging | In vitro—enzymes and substrate | UVA/UVB | Enzyme (starting concentration of 1 μg/μL) with its substrate 0.5 mM | [78] |
| Extract | Negative photobiological effects/reduction of UVB rays | In vivo—human | UVB | Oral Used dose: 480 mg/day | [7] |
| Hydrophilic extract (Fernblock) | Cell damage prevention/increased expression of matrix metalloproteinase-1 and cathepsin K/slowing expression of fibrillin 1, 2 and elastin | In vitro—cell cultures (human dermal fibroblasts) | Infrared A and visible light | Incubation | [11] |
| Extract | Decrease in darkening, cyclooxygenase-2 (marker of cell damage) | In vivo—human | Visible light | Oral Used dose: 480 mg/day | [79] |
| Extract (Fernblock) | Protective activity against oxidative stress and aging | In vitro—non-tumorigenic human keratinocyte cells | UVB | Incubation | [68] |